14th International Rotavirus Symposium

The 14th International Rotavirus Symposium took place March 14-16, 2023 in Bali, Indonesia at the Westin Nusa Dua Hotel. It brought together interested stakeholders to provide an update on new data and relevant research that will inform public health agendas related to prevention of rotavirus gastroenteritis.

Rotavirus Symposium Presentations

Day 1

Opening Session

Opening Address – Dr. Rizka Andalucia, Ministry of Health, Indonesia

Overview of Rotavirus and Rotavirus vaccines – Duncan Steele, Bill & Melinda Gates Foundation

Tribute to Prof Yati Soenarto

Session I: Rotavirus Disease and Control in Indonesia

The burden of rotavirus disease in Indonesia- Hera Nirwati, Universitas Gadjah Mada

A cost-effectiveness analysis of rotavirus vaccine for Indonesia- Jarir At Thobari, Universitas Gadjah Mada

Model based estimation of the impact on rotavirus disease of the RV3-BB vaccine administered in a neonatal or infant schedule in Indonesia
– Vicka Oktaria, Universitas Gadjah Mada

Development of the neonatal rotavirus vaccine at PT Biofarma – Adriansjah Azhari, Biofarma

Plans for implementation of Rotavirus Vaccine in Indonesia – Prima Yosephine, Ministry of Health, Indonesia

Session II: Global Rotavirus Disease burden and Impact of Rotavirus vaccines

Challenges to childhood immunization during the COVID-19 pandemic – Anuradha Gupta, Sabin Vaccine Institute

Rotavirus hospitalizations among children under 5 years of age, 2017-2021: Findings from the Global Rotavirus Surveillance Network- Heidi Soeters, World Health Organization

Etiology of hospitalized diarrhea in children in low- and middle-income countries: Results from the Global Pediatric Diarrhea Surveillance Network, 2017-2020 – James Platts-Mills, University of Virginia

Changing landscape of moderate-to-severe diarrhea among children in three sub-Saharan African countries following rotavirus vaccine introduction:  The Vaccine Impact on Diarrhea in Africa (VIDA) Study – Dilruba Nasrin, University of Maryland

Global impact of rotavirus vaccination in the pre-COVID-19 era: A modelling analysis – Sarwat Mahmud, London School of Hygiene & Tropical Medicine

Impact of rotavirus vaccination in 112 countries from 2006 to 2034 – Aniruddha Deshpande, Emory University

Session III:   Insights on rotavirus disease burden and rotavirus vaccine introduction in the Region

Rotavirus epidemiology and the potential impact of vaccination in Dhaka, Bangladesh – Ernest O Asare, Yale University

A decade long study on Group A rotavirus infection and genotype diversity among children with acute gastroenteritis in Kolkata, East India (2012-2022) – Shanta Dutta, ICMR-National Institute of Cholera and Enteric Diseases

Etiology of gastroenteritis pathogens among hospitalized children under 5 years of age in the Philippines, 2017-2019 – CEI Lazaro-Oasin, Department of Health-Research Institute for Tropical Medicine

Early impact on rotavirus disease by the monovalent Rotavac vaccine in India – Venkata Raghava, Christian Medical College Vellore

Post-introduction Evaluation in India – Veena Dhawan, Ministry of Health and Family Welfare, India

Day 2

Session IV:    Roger Glass Keynote Lecture

Roger Glass Lecture – From discovery to implementation: the journey of RV3BB to target disease prevention from birth – Julie Bines, Murdoch Childrens Research Institute

Session V:     Policy, Access and Implementation of oral rotavirus vaccines

GAVI rotavirus vaccines support: supply challenges, implementation challenges, and optimization opportunities for countries – Veronica Denti, Gavi, the Vaccine Alliance

Rotavirus vaccine product switch: Experience under the Universal Immunization Programme in India – Seema Singh Koshal, John Snow Inc.

Impact and cost-effectiveness of rotavirus vaccination in Non-Gavi Low- and Middle-Income Countries – Frederic Debellut, PATH

Rotavirus vaccine product switch in Ghana: An assessment of service delivery costs, program switch costs and cost-effectiveness – Richmond Owusu, School of Public Health, University of Ghana

Panel Discussion: Increasing rotavirus vaccine coverage-opportunities and challenges – Deborah Atherly, PATH, Zulkifli Ismail, KPJ Healthcare University College, Malaysia, Tony Nelson, Chinese University of Hong Kong Shenzhen

Session VI:  Real world impact of Rotavirus Vaccines

Impact assessment of rotavirus vaccine introduction in Pakistan’s routine immunization program – Atif Riaz, Aga Khan University

Impact and effectiveness of Rotavin-M1 under conditions of routine use in two provinces in Vietnam, 2016-2021- Nguyen Van Trang, National Institute of Hygiene and Epidemiology

Impact of the introduction of Rotarix (2016-2018) and Rotavac (since 2018) in the West Bank, Palestinian Territories – Wolfgang Rennert, Caritas Baby Hospital

Session VII:   New insights into rotavirus immune responses and virology

Induction of systemic and mucosal neutralizing antibodies to norovirus and rotavirus after oral administration of a live recombinant rotavirus to suckling mice – Harry Greenberg, Stanford University

Maternal breast milk secretor phenotype does not affect infant susceptibility to rotavirus diarrhea – Benjamin Lee, University of Vermont College of Medicine

Elevated levels of pre-existing growth factors and cytokines are associated with rotavirus vaccine take in Malawian infants – Khuzwayo Jere, Malawi-Liverpool Wellcome Trust Clinical Research Programme

RotaTeq and Rotarix rotavirus vaccines immunogenicity in malnourished infants in Bangladesh and Bolivia – Daniel Velasquez-Portocarrero, Centers for Disease Control and Prevention, US

Session VIII:    Advances in our understanding of rotavirus pathophysiology

Understanding the interplay between host, microbiome and an orally delivered probiotic rotavirus vaccine platform – Gregg Dean, Colorado State University

Harnessing the potential of the gut microbiome to improve oral rotavirus vaccine responses – Sashi Ramani, Baylor College of Medicine

Profiles and influence of maternal and infant histo-blood group antigens on oral rotavirus vaccine (Rotarix) immunogenicity in Zambia – Adriace Chauwa, Centre For Infectious Disease Research In Zambia

Rotavirus NSP4 mediated increase in intracellular calcium results in increased levels of the pro-inflammatory eicosanoid, prostaglandin E2, during infection – Hester O’Neill, University of the Free State

Host long non-coding RNAs: Key modulators in rotavirus infection dynamics – Shreya Banerjee, ICMR-National Institute of Cholera and Enteric Diseases

The role of aryl hydrocarbon receptor (AhR) signaling in determining the susceptibility to rotavirus infection – Nurul Iffat Wirusanti, Department of Global Health, Amsterdam UMC

Day 3

Session IX:   Ruth Bishop Keynote Lecture

Ruth Bishop Lecture – New Insights into Rotavirus Pathogenesis and Vaccines – Mary Estes, Baylor College of Medicine

Session X:   Advances in Understanding of Rotavirus Disease

Rotavirus in the time of SARS-CoV-2: The South African story, 2018-2022 – Nicola Page, National Institute for Communicable Diseases

Association between maternal breast milk microbiota composition and rotavirus vaccine responses in Africa, Asian and European infants – Khuzwayo Jere, Malawi-Liverpool Wellcome Trust

Immunogenicity of a third scheduled dose of Rotarix in Australian indigenous children: A Phase IV, double blind, randomized, placebo-controlled clinical trial – Bianca Middleton, University of Sydney

Comparison of rotavirus and norovirus post-rotavirus vaccine introduction in 3 sub-Saharan African countries, 2015-2018 – Richard Omore, Kenya Medical Research Institute

Interchangeable vaccine dosage algorithm for available rotavirus vaccine products in India: A pragmatic alternative to single vaccine product regimens – Suman Kanungo, ICMR-National Institute of Cholera and Enteric Diseases

Natural Killer T-cells are altered in Malawian infants immunized with the neonatal RV3-BB rotavirus vaccine – Prisca Benedicto-Matambo, Kamuzu University

Cohort study of the characteristics of neonatal rotavirus infection and the establishment of a transmission kinetic model in China – Si-Jie Wang, Fudan University Shanghai Medical College

Assessment of nutritional status and its association with clinical severity among Under 5 children admitted with diarrhea in India – Namrata Kharat, Christian Medical College Vellore

Session XI:   Rotavirus Molecular Epidemiology pre- and post-vaccine introduction

Rotavirus genotype distribution after the introduction of rotavirus vaccines in India, 2016-2020 – Tintu Vargese, Christian Medical College Vellore

Genotypic surveillance and epidemiologic trends of rotavirus infection among children with gastroenteritis in Bangladesh, 2014-2021 – Shuvra Kanti Dey, Jahangirnagar University, Dhaka

Genomic constellation of human G8 strains in Brazil over a 13-year period: Detection of the novel bovine-like G8P[8] DS-1-like virus – Adriana Luchs, Adolfo Lutz Institute

Epidemiology of enteric viruses in children Under 5-years before and after rotavirus vaccine introduction in Maniçha District, Mozambique, 2007-2019 – Percina Chirinda, Manhiça Health Research Center

Characterizing the diversity of unusual rotavirus strains in Australian children and adults –  Celeste Donato, Murdoch Childrens Research Institute

The molecular epidemiology of human rotavirus and strain diversity in Kenya pre- and post- rotavirus vaccine introduction: A review – Grace Irimu, University of Nairobi, Kenya

Session XII:   Progress towards next generation rotavirus vaccines

Interim results from a phased 3 trial of a parenteral rotavirus vaccine candidate in healthy infants in Africa – Tushar Tewari, PATH

Progress towards clinical trial of inactivated rotavirus vaccine – Baoming Jiang, Centers for Disease Control and Prevention, US

Potential impact and cost-effectiveness of injectable, next generation rotavirus vaccines in 137 LMICs: A modelling study – Frederic Debellut, PATH

Session XIII:  Closing Ceremony

Best Poster Award Winners:
·        Allison Vilander
·        Anupama Machathi
·        Lerato Kgosana
·        Ly Thi Khanh Le
·        Pempa Pempa
·        Warda Haque

Closing address – Cherry Kang, Christian Medical College Vellore